



JMCC CEO Diane Scott Appointed as Founding Partner of U.K.'s Centre for Medicinal Cannabis

London/January 30, 2019 – The Centre for Medicinal Cannabis (CMC) today announced the appointment of Diane Scott, Chair and Chief Executive Office of Canadian-headquartered Jamaican Medical Cannabis Corporation, as a Founding Partner of the London-based CMC.

Founded in 2018, the CMC is a non-profit organization working to shape the UK's new medicinal cannabis regime in the interests of patients. Its focus is on promoting public understanding, political engagement, policy advocacy and clinical education around the use of medicinal cannabis.

The CMC is actively engaging with the Department of Health and Social Care, the Home Office, the National Institute for Health and Care Excellence (NICE), and all relevant public authorities on behalf of the potentially millions of people in the UK who will benefit from a successful implementation of policy relating to medicinal cannabis.

As Founding Partner, Ms. Scott will play an important advisory role given the advanced nature of medicinal cannabis production and treatment in North America. As one of the few female CEOs of an enterprise engaged in medical cannabis production – from cultivation and processing, through to packaging and global distribution – she brings a unique viewpoint to her advisory role with the CMC. In addition, with JMCC's operations in Jamaica, contracted customers in Canada, Australia and Germany, and a robust, global B2B marketing platform, Ms. Scott can also contribute an international perspective, knowledge of best practices and a global contact network to CMC initiatives.

“We're very enthused about Diane joining the CMC in this advisory role,” said Steven Moore, CMC's Strategic Counsel. “Her energy, business savvy and international experience will assist us in reaching out to like-minded organizations – in the public, private and NGO sectors worldwide – to share information and insight.”

“I am thrilled to be able to contribute to the CMC's goals via this appointment,” Ms. Scott said. “I believe its proposals for thoughtful and responsible medical cannabis regulation, if adopted by the U.K. government, will set a new example for other countries contemplating the best way to make medical cannabis available to patients.”

About the Centre for Medicinal Cannabis and Cannabis Law Reform in the U.K.

The CMC was founded in 2018 by a group of philanthropists, scientists, campaigners, public policy experts and educators to advance responsible, ethical and evidence-based access to medicinal cannabis. Its founding team includes the core group, led by Steve Moore, who successfully directed the campaign on behalf of Billy Caldwell, a 12-year-old from Northern Ireland suffering from severe epilepsy, who travelled to Canada in mid-2018 with his mother, Charlotte Caldwell, to procure a prescription for and a supply of medical cannabis oil to treat his epilepsy, which was then confiscated by UK customs on their return.

A huge public outcry prompted newly appointed Conservative Home Secretary, Sajid Javid MP, to initiate an urgent review of cannabis-based medicinal products. Within weeks he had received advice and accepted recommendations from the Advisory Council on the Misuse of Drugs (ACMD) and the UK's Chief Medical Officer that cannabis had proven medical benefits and that the government should proceed with rescheduling approved cannabis-based medicines to Schedule 2, which it did in October. It also issued temporary prescribing rules for cannabis-based medicines, which are in effect until the government introduces a comprehensive regulatory regime.

In theory, this means cannabis-based medicines can now be prescribed. In practice, the NHS has warned that “very few people are likely to get a prescription for medical cannabis” because of the tight restrictions that were put place.

In December, the CMC [issued an in-depth report](#) with 60 evidence-based recommendations, and which proposes “a credible and compelling model” for the UK's first medicinal cannabis regime. The CMC plans to continue working with policy-makers, medical researchers and practitioners, patients and other stakeholders to influence how the new system is designed and implemented over the course of 2019.

About Jamaican Medical Cannabis Corporation Ltd. (JMCC)

JMCC is a Canadian-headquartered group of companies with rapidly expanding medical cannabis operations in Jamaica, including a cultivation “collective” of small farmers. It provides a range of cultivars sun-grown in specially designed greenhouses at various locations around the island. Led by an international executive team with in-depth experience in highly regulated industries, JMCC provides premium medicinal cannabis and a range of processing/extraction, packaging, and international warehousing and distribution services to licensed producers and other industry participants to free them to focus on creating and delivering the best products for patients.

For more information, please visit www.jamaicanmedicann.com.

Media Contact for JMCC:

Shelley Boyes

Global Director, Marketing & Communications

T: +1 416 272 8981

E: shelley.boyes@jamaicanmedicann.com